A randomised controlled trial with rivaroxaban and apixaban in the treatment for venous thromboembolism in cancer patients

A randomised controlled trial with rivaroxaban and apixaban in the treatment for venous thromboembolism in cancer patients - Comparison between rivaroxaban and apixaban in the treatment for venous thromboembolism in cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026600

Enrollment

100

Registered

2017-03-17

Start date

2017-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism with cancer patients

Interventions

take rivaroxaban take apixaban

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Venous thromboembolism of cancer patients

Exclusion criteria

Exclusion criteria: hemorrhage patients Contra-indication to the treatment

Design outcomes

Primary

Measure	Time frame
Recurrence of venous thromboembolism Hemorrhage	—

Countries

Japan

Contacts

Public ContactYuzo Hasegawa

Chiba Cancer Center Neurological Surgery

yhasegawa@chiba-cc.jp043-264-5431

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026